Aerie Pharmaceuticals, Inc.
https://aeriepharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aerie Pharmaceuticals, Inc.
Aldeyra Looking At Paths To Approval In Dry Eye After Phase III Miss
Firm revises second Phase III trial for co-primary endpoints, possibly improving its chances of success for demonstrating efficacy on a sign of dry eye disease. Initial Phase III study missed ocular redness measure.
Ocular’s OTX-DED Succeeds In Dry Eye Where OTX-CSI Failed, But More Data Needed
The Phase II trial showed significant improvement in eye redness in patients with dry eye disease, but additional data are needed on DED symptom improvement.
Aerie Misses Quick Path To Dry Eye Approval, But Is Still Moving Forward
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.
Phesgo & Roclanda Among New Winners At EMA
The European Medicines Agency this week recommended that five new products be granted EU marketing approval.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Avizorex Pharma, S.L.